Most Read

These studies are expected to begin in 2019. Naptumomab is the lead drug in NeoTX’s novel Selective T cell Redirection (“STR”) platform. Naptumomab’s dual mechanism of action coats

B-cell maturation antigen (BCMA) has emerged as an attractive target for multiple myeloma therapeutics. TNB-383B is a bispecific antibody that simultaneously targets BCMA and CD3, utilizing Teneobio’s unique

The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS (ranibizumab) and SOLIRIS (eculizumab), respectively, as well as SB3,

The collaboration concerns a small molecule programme, currently in pre-clinical development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified

The new company will focus on the development of a novel family of small molecule inhibitors designed to block tumor growth and stimulate the immune system to fight

Recida’s lead program, RC-01, is a novel, IND-stage LpxC inhibitor for the treatment of multidrug-resistant gram-negative infections. Recida has licensed development and commercialization rights to RC-01 from FUJIFILM

Construction of the additional packaging suites began in March 2018 to add considerable footprint for primary and secondary packaging operations equipped with high speed tablet filling, cartoning, as

The contract from the Small Business Research Initiative (“SBRI”), administered by Innovate UK, will be used to make the Company’s epidermicin NI01 antibiotic ready for phase 1 human

Data were presented at the Sleep Research Society’s Advances in Sleep and Circadian Science conference, taking place in Clearwater Beach, Florida, Feb. 1-4, 2019. SUNRISE 2 was a